Curaleaf Eyes Nasdaq Uplisting as Cannabis Rescheduling Momentum Builds
Multi-state operator positions for major exchange listing as federal rescheduling creates pathway for institutional investment access.
Curaleaf Holdings, one of the largest cannabis multi-state operators in the U.S., is positioning itself for a potential stock uplisting to a major exchange as federal cannabis rescheduling efforts gain traction. The Massachusetts-based company currently trades on the Canadian Securities Exchange and over-the-counter markets, but federal rescheduling from Schedule I to Schedule III would remove key barriers preventing cannabis companies from listing on the Nasdaq or NYSE.
The uplisting preparation reflects broader industry anticipation that the DEA will finalize the rescheduling process initiated by the Biden administration earlier this year. Cannabis companies have faced significant capital market constraints due to their Schedule I classification, forcing them to rely on limited financing options and excluding them from major U.S. exchanges. This has kept institutional investors largely on the sidelines, constraining valuations across the sector.
For Curaleaf, which operates 145 dispensaries across 17 states and generated $1.3 billion in revenue over the past twelve months, uplisting would provide access to a much deeper pool of institutional capital. The company has maintained one of the stronger balance sheets among MSOs, with approximately $100 million in cash and manageable debt levels, positioning it well for the compliance requirements that come with major exchange listings.
The timing aligns with broader consolidation trends in the cannabis industry, where scale and capital access increasingly determine competitive positioning. Companies like Green Thumb Industries and Trulieve Cannabis have similarly prepared for potential uplisting scenarios, recognizing that access to institutional capital could accelerate market share gains and operational expansion.
While the rescheduling timeline remains uncertain, with potential delays extending into 2025, cannabis operators are treating uplisting preparation as a strategic priority rather than speculative positioning. The companies that successfully navigate the transition to major exchanges will likely capture disproportionate institutional investment flows, creating a clear competitive advantage in an industry still constrained by federal prohibition dynamics.